Health-related quality of life and costs of receiving add-on therapy with insulin glargine or pioglitazone in patients with type 2 diabetes

被引：0
|
作者：
Meneghini, L.
Schwartz, S.
Strange, P.
Oster, G.
机构：
[1] Univ Miami, Miller Sch Med, Coral Gables, FL 33124 USA
[2] Diabet & Glandular Dis Res Associates, San Antonio, TX USA
[3] Sanofi Aventis US, US Med Affairs, Bridgewater, MA USA
[4] Policy Anal Inc, Brookline, MA USA
来源：
DIABETOLOGIA | 2006年 / 49卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0894
引用
收藏
页码：543 / 543
页数：1
相关论文
共 50 条
  • [21] Evaluation of add-on therapy of sitagliptin in Japanese patients with type 2 diabetes under insulin therapy
    Nakagami T.
    Ide R.
    Iwasaki N.
    Ogata M.
    Oya J.
    Osawa M.
    Tanaka N.
    Takaike H.
    Sato A.
    Miura J.
    Uchigata Y.
    Diabetology International, 2014, 5 (3) : 187 - 197
  • [22] Health-related quality of life in patients with diabetes mellitus -: Type 1 and type 2
    Prütz, C
    Suchdev, S
    Jansson-Blixt, C
    Toft, E
    VALUE IN HEALTH, 2006, 9 (03) : A41 - A41
  • [23] Insulin glargine improves health related quality of life in patients with type 2 diabetes inadequately controlled on sulfonylurea plus metformin
    Vinik, AI
    Dailey, G
    Zhang, Q
    DIABETOLOGIA, 2005, 48 : A312 - A312
  • [24] PREDICTIVE FACTORS FOR HEALTH-RELATED QUALITY OF LIFE IN TYPE 2 DIABETES PATIENTS
    Grigorescu, Elena-Daniela
    Lacatusu, Cristina- Mihaela
    Cazac, Georgiana-Diana
    Onofriescu, Alina
    Floria, Mariana
    Cretu, Ioana
    Mihai, B. M.
    MEDICAL-SURGICAL JOURNAL-REVISTA MEDICO-CHIRURGICALA, 2024, 128 (03): : 478 - 489
  • [25] Valuing Health-Related Quality of Life in Type 2 Diabetes Patients in China
    Pan, Chen-Wei
    Sun, Hong-Peng
    Zhou, Hui-Jun
    Ma, Qinghua
    Xu, Yong
    Luo, Nan
    Wang, Pei
    MEDICAL DECISION MAKING, 2016, 36 (02) : 234 - 241
  • [26] The Health-Related Quality of Life of Patients with Type 2 Diabetes in Saudi Arabia
    AbuAlhommos, Amal Khaleel
    Alturaifi, Amjad Heji
    Al-Bin Hamdhah, Amnah Mohammed
    Al-Ramadhan, Hawra Hassan
    Al Ali, Zahra Abdullah
    Al Nasser, Hawra Jumah
    PATIENT PREFERENCE AND ADHERENCE, 2022, 16 : 1233 - 1245
  • [27] Efficacy and Safety of Linagliptin as Add-On Therapy to Basal Insulin in Patients With Type 2 Diabetes
    Yki-Jarvinen, Hannele
    Duran-Garcia, Santiago
    Pinnetti, Sabine
    Bhattacharya, Sudipta
    Thiemann, Sandra
    Patel, Sanjay
    Woerle, Hans-Juergen
    DIABETES, 2012, 61 : A255 - A255
  • [28] HEALTH-RELATED QUALITY OF LIFE OF TYPE 2 DIABETES AND HYPERTENSION PATIENTS IN SLOVENIA
    Rupel, Prevolnik, V
    Ogorevc, M.
    Poplas-Susic, A.
    VALUE IN HEALTH, 2020, 23 : S620 - S620
  • [29] Dapagliflozin as Add-On Therapy in Asian Patients with Type 2 Diabetes Inadequately Controlled on Insulin
    Yang, Wenying
    Ma, Jianhua
    Li, Yiming
    Li, Yanbing
    Zhou, Zhiguang
    Kim, Jae Hyeon
    Zhao, June
    Ptaszynska, Agata
    DIABETES, 2017, 66 : A338 - A338
  • [30] Use of dapagliflozin as an add-on to insulin therapy in patients with suboptimally controlled type 2 diabetes
    Das, Gautam
    Surya, Ashutosh
    Abusahmin, Hussam
    THERAPEUTIC ADVANCES IN ENDOCRINOLOGY AND METABOLISM, 2018, 9 (08) : 269 - 270
12345